Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Center for Advancing Translational Sciences (NCATS) | NIH |
Not provided
Not provided
Not provided
Not provided
Not provided
This study will examine markers of vascular endothelial function (vascular health) and metabolic profiles in younger versus older transgender women (people who were assigned male at birth but whose gender identity is female). Data will also be compared to those from cisgender women and men.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Older transgender women | This cohort will consist of transgender women aged 50-75 years old who have taken estradiol and spironolactone for at least one year. |
| |
| Younger transgender women | This cohort will consist of transgender women aged 18-40 years old who have taken estradiol and spironolactone for at least one year. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| No intervention | Other | There was no intervention in this study |
|
| Measure | Description | Time Frame |
|---|---|---|
| Evaluation of endothelial function (flow-mediated dilation (FMD) | Brachial artery flow-mediated dilation (FMD), as measured by ultrasound. | Baseline |
| Measure | Description | Time Frame |
|---|---|---|
| Evaluation of carotid artery compliance | The carotid artery compliance index indicates how elastic the artery is. The index describes the change in arterial blood volume in response to a change in arterial blood pressure. Lower numbers are associated with worse outcomes (less elastic arteries). | Baseline |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Transgender women (people who were assigned male at birth but whose gender identity is female). They may or may not have legally changed their gender marker.
Transgender women from the Denver metropolitan area and/or who utilize health care at University of Colorado Hospital.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Sean Iwamoto, MD | University of Colorado, Denver | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Colorado | Aurora | Colorado | 80045 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Endothelial cells
| Evaluation of carotid artery beta stiffness index |
The carotid artery beta stiffness index indicates how stiff the artery is. Higher numbers are associated with worse outcomes (stiffer artery). |
| Baseline |
| Carotid artery intimal-medial thickness | Baseline |
| Evaluation of oxidant burden: oxidized LDL | Oxidized low-density lipoprotein (LDL) measured in the blood and endothelial cells. | Baseline |
| Evaluation of oxidant burden: nitrotyrosine | Nitrotyrosine measured in the blood and endothelial cells. | Baseline |
| Evaluation of vascular endothelial cell inflammation: NFkB | Protein NFkB (nuclear factor kappa-light-chain-enhancer of activated B cells) measured in blood and endothelial cells. | Baseline |
| Evaluation of vascular endothelial cell inflammation: MCP-1 | Monocyte Chemoattractant Protein-1 (MCP-1) measured in blood and endothelial cells. | Baseline |
| Evaluation of vascular endothelial cell inflammation: IL-6 | Interleukin 6 (IL-6) measured in blood and endothelial cells. | Baseline |
| Evaluation of vascular endothelial cell inflammation: CRP | C-reactive protein (CRP) measured in blood and endothelial cells. | Baseline |
| Blood pressure | Baseline |
| Plasma lipid concentrations: total cholesterol | Total cholesterol will be determined at baseline. | Baseline |
| Plasma lipid concentrations: triglycerides | Triglycerides will be determined at baseline. | Baseline |
| Insulin sensitivity | Baseline |
| Whole body composition: Percent Lean Mass | Percent lean mass will be determined using dual energy x-ray absorptiometry. | Baseline |
| Whole body composition: Percent Fat Mass | Percent fat mass will be determined using dual energy x-ray absorptiometry. | Baseline |
| Regional body composition: Percent Lean Mass | Regional percent lean mass will be determined using dual energy x-ray absorptiometry. | Baseline |
| Regional body composition: Percent Fat Mass | Regional percent fat mass will be determined using dual energy x-ray absorptiometry. | Baseline |
| Weight changes | Baseline |
| Appetite ratings | Baseline |
| Appetite-related peptides | Baseline |
| D-Dimer | Baseline |
| Alcohol use | Baseline |
| Depression symptoms | Baseline |
| Physical activity monitoring | Physical activity will me monitored for 7 days with an ActivPALmonitor | 7 days |
| Energy intake | Energy intake will be estimated with a 3-day food diary | 3 days |
| ID | Term |
|---|---|
| D007333 | Insulin Resistance |
| D052439 | Lipid Metabolism Disorders |
| D001070 | Appetitive Behavior |
| ID | Term |
|---|---|
| D006946 | Hyperinsulinism |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D001522 | Behavior, Animal |
| D001519 | Behavior |
Not provided
Not provided